Herceptin Adjuvant (HERA) Trial Study Team. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial - Gianni, L; Dafni, U; Gelber, R D (Lancet Oncol, 2011)
et al